Article: RECEPTAGEN INITIATES CLINICAL DEVELOPMENT OF GROWTH BLOCKERS-DRUG CANDIDATE DEMONSTRATES "PROGRAMMED CELL DEATH" IN CANCER CELLS.

SEATTLE, WASH--(BUSINESS WIRE)--FEBRUARY 15, 1995--RECEPTAGEN LTD.(TSE: RCG ) Receptagen Ltd. today announced it has begun formal clinical development of its first "growth blocker" drug, as a result of recent company research demonstrating selective induction of programmed cell death, or "apoptosis", in cancer cells.

Receptagen is developing growth blocker drugs, a new class of minimally toxic biopharmaceuticals for the treatment of cancer and other life-threatening diseases marked by uncontrolled cell proliferation. With recent efficacy shown in cells, it has initiated development of the first generation of growth blockers that potentially lack the toxicities and ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!